Recombinant Activated Factor VII Administration after Pulmonary Embolectomy: Case Report
DOI:
https://doi.org/10.1532/HSF98.20131026Abstract
Bleeding management in cardiac surgery could be a great challenge for the surgeon and a life-threatening moment for the patient. Despite the fact that recombinant activated factor VII is now widely accepted as a useful adjunct in the management of postcardiotomy coagulopathy, its use in the course of recent thromboembolic event is rarely described. We hereby present a case of rescue recombinant activated factor VII administration to manage a severe coagulation disorder during surgical pulmonary embolectomy performed under cardiopulmonary bypass.References
Goldhaber SZ, Haire WD, Feldstein ML, et al. 1993. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 341:507-511.nKasper W, Konstantinides S, Geibel A, et al. 1997. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 30:1165-1171.nLehr EJ, Alford TJ, Wang SH. 2010. Recombinant activated factor VII for postoperative hemorrhage following repair of acute type A aortic dissection. Heart Surg Forum 13:E275-9.nLevi M, Peters M, Büller HR. 2005. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 33:883-890.nMeneveau N, Séronde MF, Blonde MC, et al. 2006. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 129:1043-1050.nMeneveau N. 2010. Therapy for acute high-risk pulmonary embolism: thrombolytic therapy and embolectomy. Curr Opin Cardiol 25:560-567.nThabut G, Thabut D, Myers RP, et al. 2002. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 40:1660-1667.nReyes G, Carrasco N, Muñoz T, Duarte J. 2008. Management of massive pulmonary embolism using recombinant activated Factor VII. Eur J Cardiothorac Surg 33:1144-1145.n
